These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 24267459

  • 1. Management of a hyperactive teen and cardiac safety.
    Sowinski H, Karpawich PP.
    Pediatr Clin North Am; 2014 Feb; 61(1):81-90. PubMed ID: 24267459
    [Abstract] [Full Text] [Related]

  • 2. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 3. Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.
    Merkel RL.
    Expert Opin Drug Saf; 2010 Nov; 9(6):917-35. PubMed ID: 20615078
    [Abstract] [Full Text] [Related]

  • 4. [Cardiovascular risk assessment for the use of ADHD drugs in children].
    Berg A, Bråtane E, Odland HH, Brudvik C, Rosland B, Hirth A.
    Tidsskr Nor Laegeforen; 2014 Apr 08; 134(7):710-4. PubMed ID: 24721858
    [Abstract] [Full Text] [Related]

  • 5. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J, Knecht C, Szerman N, Martinez MI.
    CNS Drugs; 2013 Jan 08; 27(1):15-30. PubMed ID: 23160939
    [Abstract] [Full Text] [Related]

  • 6. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S.
    Curr Opin Pediatr; 2016 Oct 08; 28(5):607-12. PubMed ID: 27261563
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.
    J Am Acad Child Adolesc Psychiatry; 2011 Oct 08; 50(10):978-90. PubMed ID: 21961773
    [Abstract] [Full Text] [Related]

  • 8. Stimulants and sudden death: what is a physician to do?
    Wilens TE, Prince JB, Spencer TJ, Biederman J.
    Pediatrics; 2006 Sep 08; 118(3):1215-9. PubMed ID: 16951018
    [Abstract] [Full Text] [Related]

  • 9. Attention-deficit hyperactivity disorder.
    Calis KA, Grothe DR, Elia J.
    Clin Pharm; 1990 Aug 08; 9(8):632-42. PubMed ID: 1974836
    [Abstract] [Full Text] [Related]

  • 10. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P.
    Child Care Health Dev; 2006 Sep 08; 32(5):575-83. PubMed ID: 16919137
    [Abstract] [Full Text] [Related]

  • 11. Attention-deficit/hyperactivity disorder and sleep disorders in children.
    Tsai MH, Huang YS.
    Med Clin North Am; 2010 May 08; 94(3):615-32. PubMed ID: 20451036
    [Abstract] [Full Text] [Related]

  • 12. Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.
    Noorbala AA, Akhondzadeh S.
    Arch Iran Med; 2006 Oct 08; 9(4):374-80. PubMed ID: 17061613
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR, Skimming JW, Muniz R.
    Clin Pediatr (Phila); 2010 Sep 08; 49(9):840-51. PubMed ID: 20693523
    [Abstract] [Full Text] [Related]

  • 14. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
    Bricard C, Boidein F.
    Encephale; 2001 Sep 08; 27(5):435-43. PubMed ID: 11760693
    [Abstract] [Full Text] [Related]

  • 15. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun 08; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 16. Dexmethylphenidate for attention deficit hyperactivity disorder.
    Coury D.
    Expert Opin Pharmacother; 2009 Nov 08; 10(16):2679-85. PubMed ID: 19874250
    [Abstract] [Full Text] [Related]

  • 17. Attention-deficit/hyperactivity disorder: management.
    Szymanski ML, Zolotor A.
    Am Fam Physician; 2001 Oct 15; 64(8):1355-62. PubMed ID: 11681777
    [Abstract] [Full Text] [Related]

  • 18. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M.
    Pediatrics; 2007 Jan 15; 119(1):154-5. PubMed ID: 17200281
    [No Abstract] [Full Text] [Related]

  • 19. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun 15; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P, Sever J, Weizman A.
    Harefuah; 2011 Oct 15; 150(10):788-90, 814. PubMed ID: 22111124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.